News
-
According to Texas-based CDMO Matica Biotechnology, the company will provide development and manufacturing services to vaccine developer VaxDome, also based in Texas, to advance a VaxDome intranasal antiviral / vaccine candidate into clinical trials. Matica… Read more . . .
-
According to Sino Biopharmaceutical, AstraZeneca will pay $200 million up front and a total of up to $1.9 billion for the development, manufacturing, and commercialization rights to Sino Biopharm’s TQC3721 inhaled PDE3/4 inhibitor outside of… Read more . . .
-
ARS Pharmaceuticals, whose only product is neffy epinephrine nasal spray, announced that long-time CEO Richard Lowenthal has left the company and that Donn Casale, has taken over as CEO and Director. Casale joined ARS Pharma… Read more . . .
-
Nebulizer developer Nebu-Flow, which recently received a £2 million Scottish Enterprise grant, announced that it has been invited to join the Innovate UK Scaleup Programme, which will provide access to a “virtual executive team.” The… Read more . . .
-
The Australian Medical Research Future Fund (MRFF) Frontier Health and Medical Research Initiative is providing over AU $15 million to Atisama Therapeutics (formerly Rage Bio) and Monash University to support continued development of RB042 inhaled… Read more . . .
-
Vistagen has announced that the Phase 3 PALISADE-4 public speaking challenge study of intranasal fasedienol (PH94B) for the treatment of social anxiety disorder failed to meet its primary endpoint. In December 2025, the company announced… Read more . . .
-
Insmed has hired former Johnson & Johnson executive Samuele Butera as Senior VP, General Manager, Global Respiratory, the company said. Butera previously served in executive positions at Sandoz and Novartis before joining Johnson & Johnson,… Read more . . .
-
Canadian biotech Zymeworks has agreed to pay $17 per share, a total of approximately $929 million, to acquire Theravance Biopharma, the companies have announced. The deal, which is subject to approval by Theravance shareholders, is… Read more . . .
-
The European Innovation Council Fund, Invest-NL, Gates Foundation, and ClavystBio are among those contributing to a €40 million financing to support development of Leyden Laboratories’ antiviral nasal sprays the company said. Since the beginning of… Read more . . .
-
University of St Andrews spin out Pneumagen has reorganized as a US-based company called NorthLinks Bio, the company said, though research will continue in Scotland. Pneumagen CEO Douglas Thomson has joined the board of the… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK